CCP-07 regulatory update

FDA issued a complete response letter to an NDA from Vernalis for CCP-07 to treat cough and cold. The company said the CRL did not identify issues with the candidate's formulation or pharmacokinetic profile, but declined to discuss further details. Vernalis plans to resubmit the NDA “as quickly as possible.”...